Compare ICCM & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ICCM | GRF |
|---|---|---|
| Founded | 2006 | 1989 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 42.6M |
| IPO Year | N/A | N/A |
| Metric | ICCM | GRF |
|---|---|---|
| Price | $0.67 | $10.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 363.1K | 3.0K |
| Earning Date | 11-19-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | ★ $2,975,000.00 | N/A |
| Revenue This Year | $13.67 | N/A |
| Revenue Next Year | $38.55 | N/A |
| P/E Ratio | ★ N/A | $8.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $7.93 |
| 52 Week High | $1.66 | $10.19 |
| Indicator | ICCM | GRF |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 47.46 |
| Support Level | $0.61 | $11.16 |
| Resistance Level | $0.72 | $11.85 |
| Average True Range (ATR) | 0.04 | 0.32 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 51.61 | 30.77 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.